NasdaqCM - Nasdaq Real Time Price USD

IN8bio, Inc. (INAB)

0.9199 -0.0602 (-6.14%)

As of 1:34:26 PM EDT. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 23d ago

INAB
-6.14%
IN8bio to Present at Sidoti Small-Cap Virtual Conference

GlobeNewswire 1mo ago

INAB
-6.14%
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

GlobeNewswire 1mo ago

INAB
-6.14%
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2mo ago

INAB
-6.14%
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire 2mo ago

INAB
-6.14%
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

GlobeNewswire 3mo ago

INAB
-6.14%
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

GlobeNewswire 5mo ago

INAB
-6.14%
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire 5mo ago

INAB
-6.14%
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

GlobeNewswire 5mo ago

INAB
-6.14%
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 6mo ago

INAB
-6.14%
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire 1mo ago

INAB
-6.14%
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

GlobeNewswire 4mo ago

INAB
-6.14%

Performance Overview

Return	INAB	S&P 500 (^GSPC)
YTD	-60.69%	+10.66%
1-Year	-53.77%	+11.03%
3-Year	-96.74%	+81.80%

U.S. markets close in 2h 16m

IN8bio, Inc. (INAB)

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026